# A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

> **NCT01846416** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 138 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

## Key facts

- **NCT ID:** NCT01846416
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-30
- **Primary completion:** 2015-01-07
- **Final completion:** 2017-12-18
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846416, "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01846416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*